ClearPoint Neuro Inc is a commercial-stage medical device company that develops and commercializes integrated systems used in minimally invasive neurosurgical procedures in the brain. The company's business consists of two integrated components: a business providing medical devices for neurosurgical applications, and a business focused on partnerships in the biologics and drug delivery space. The Company operates in one reportable segment.
Last trade$8.07
Day change-$0.23 (-2.77%)
Day range$7.83 – $8.32
Volume353,112
Market cap$266M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$266.05M
Price / earnings
—
Price / book
9.76×
Price / sales
5.85×
EV / sales
5.95×
EV / EBITDA
-9.97×
Profitability
Earnings per share
-$1.13
Return on assets
-32.06%
Return on equity
-132.52%
Dividend yield
0%
Liquidity and leverage
Debt / equity
1.86×
Current ratio
6.76×
Quick ratio
5.77×
Cash ratio
4.68×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$33.22M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for CLPT, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$12.08M
$10.88M
$12.13M
$10.41M
$8.86M
$9.22M
$8.49M
$7.77M
Cost of revenue
$5.02M
$4.17M
$4.37M
$4.01M
$3.26M
$3.66M
$3.35M
$3.01M
Gross profit
$7.06M
$6.71M
$7.76M
$6.4M
$5.6M
$5.56M
$5.13M
$4.76M
Selling, general and administrative
$9.37M
$12.32M
$11.71M
$10.21M
$7.42M
$7.41M
$7.92M
$7.07M
Research and development
$4.02M
$4.63M
$4.52M
$3.24M
$3.45M
$3.83M
$3.38M
$3.33M
Total operating expenses
$13.39M
$16.95M
$16.23M
$13.45M
$10.88M
$11.24M
$11.3M
$10.4M
Operating income
-$6.33M
-$10.24M
-$8.48M
-$7.05M
-$5.28M
-$5.68M
-$6.16M
-$5.64M
Interest expense
-$1.45M
-$1.41M
-$1.38M
-$1.92M
-$939K
-$365K
$0
-$1.16M
Income before taxes
-$7.46M
-$11.38M
-$9.54M
-$7.78M
-$5.88M
-$5.81M
-$6.01M
-$5.42M
Income taxes
-$4K
-$38K
$8K
$4K
$8K
$25K
$18K
-$32K
Net income
-$7.46M
-$11.34M
-$9.55M
-$7.79M
-$5.89M
-$5.84M
-$6.03M
-$5.39M
Net income attributable to common shareholders
-$7.46M
-$11.34M
-$9.55M
-$7.79M
-$5.89M
-$5.84M
-$6.03M
-$5.39M
EBITDA
-$4.71M
-$8.87M
-$7.37M
-$6.19M
-$4.85M
-$5.05M
-$5.83M
-$5.17M
Basic earnings per share
-$0.24
-$0.38
-$0.32
-$0.27
-$0.21
-$0.21
-$0.22
-$0.20
Diluted earnings per share
-$0.24
-$0.38
-$0.32
-$0.27
-$0.21
-$0.21
-$0.22
-$0.20
Recent news
Company coverage with links to the original publishers.
ClearPoint Neuro reported a Q3 loss of $0.24 per share, beating expectations of $0.32 loss, but missed revenue estimates with $12.08 million versus consensus. The company has underperformed the S&P 500 by 41% year-to-date and carries a Zacks Rank #3 (Hold) rating with mixed estimate revisions.
Idexx Laboratories is expected to report Q3 2026 earnings on November 2, with Wall Street anticipating year-over-year earnings growth of 9.1% to $3.71 per share and revenue growth of 7.5% to $1.19 billion. The company has a positive Earnings ESP of +0.59% combined with a Zacks Rank #2 (Buy), suggesting a likely earnings beat. Idexx has beaten consensus EPS estimates in all four of the last quarters.
Pomerantz LLP is investigating potential securities fraud claims against ClearPoint Neuro following a significant stock price decline. On September 29, 2026, development partner uniQure announced that their joint treatment for Huntington's disease failed to achieve statistical significance on a primary clinical measure at 48 months, causing ClearPoint's stock to plummet 23.12% to $11.77 per share.
AngioDynamics reported a quarterly loss of $0.04 per share, beating consensus estimates of $0.10 loss by 60%, but missed revenue expectations with $80.92 million versus the estimated $81.85 million. The medical device company has a Zacks Rank #3 (Hold) rating with mixed estimate revisions. The Medical-Instruments industry ranks in the top 39% of Zacks industries.
The global MRI-guided neurosurgical ablation market is expected to grow significantly, reaching a value of USD 227.56 million by 2034, driven by advancements in technology, regulatory approvals, and enhanced healthcare accessibility.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.